250+ investors that invest in your industry and stage
Any industry
Energy
Proptech
Community
Health Care
Gaming
Artificial Intelligence
Climate
Biotech
Impact
Google
EdTech
Sustainability
Venture Capital
Clean Energy
Finance
Retail
Infrastructure
Digital Media
Local
Enterprise Software
Email
Travel
Recruiting
Platforms
Fitness
Wine and Spirits
Crowdfunding
Social
CleanTech
Mobile Apps
InsurTech
LGBT
Non Profit
Oil and Gas
Fashion
Theatre
Renewable Energy
Sporting Goods
Social Impact
Celebrity
Cryptocurrency
SaaS
Restaurants
Machine Learning
Facebook
Agriculture (AgTech)
Media (Entertainment)
Blockchain
Publishing
Beauty
Real Estate
Life Science
B2B
Film
Web3
Big Data
Organic Food
Video Games
Medical Device
Medical
Wellness
Education
Payments
Art
Social Media
Photography
Music
Franchise
Android
Mobile
Internet
Legal
Construction
eSports
Manufacturing
Sports
Automotive
Hospitality
Financial Services
Mobile Advertising
Cannabis
Biotechnology
FinTech
Consumer
Marketplace
Hardware
Transportation
Food and Beverage
Social Network
Enterprise
Software
Any country
Australia
South Korea
Europe
Brazil
Indonesia
Singapore
Saudi Arabia
Africa
Oceania
LATAM
Asia
Middle East
Costa Rica
Gibraltar
Bahrain
Greece
Liberia
Mexico
Lebanon
Norway
Mauritius
Italy
Israel
Taiwan
Tunisia
Zambia
Russian Federation
Tajikistan
Sweden
Zimbabwe
Togo
Puerto Rico
San Marino
Nigeria
Jamaica
Honduras
Isle of Man
Mozambique
Luxembourg
Albania
Pakistan
Romania
Bangladesh
Finland
Algeria
Kenya
Kazakhstan
Cayman Islands
Cambodia
Oman
Colombia
Cameroon
Guatemala
China
Seychelles
Ireland
New Zealand
Cyprus
India
Germany
Canada
United Kingdom
Qatar
South Africa
Spain
Sri Lanka
Armenia
Azerbaijan
Austria
Barbados
Argentina
Vietnam
United Arab Emirates
Bulgaria
Belarus
Estonia
Belgium
Bermuda
Bolivia
Egypt
France
Bahamas
Czech Republic
Chile
Denmark
Faroe Islands
Georgia
Ecuador
Belize
Croatia
Dominican Republic
Hong Kong
Switzerland
Ethiopia
Grenada
Ghana
Iraq
Hungary
Iceland
Jersey
Jordan
Kuwait
Liechtenstein
Lithuania
Morocco
Latvia
Mali
Marshall Islands
Myanmar
Malta
Malaysia
Nicaragua
Namibia
Peru
Philippines
Poland
Panama
Portugal
Rwanda
Sierra Leone
Serbia
Slovenia
Senegal
El Salvador
Thailand
Tanzania
Uruguay
Turkey
Ukraine
Uganda
Uzbekistan
Venezuela
Japan
United States
Angel Investors
VC Funds
All Investors
Download Find emails Save list

Top 50 Life Science VC Funds & Investors (June 2026)

The most active venture capital funds investing in Life Science startups. This investor list is updated monthly from the Shizune investor database, ranked by number of investments in Life Science startup companies. Find investors to raise a Seed, Series A or Series B round with Shizune.
Investor Relevant Deals Geography Stage Focus Round Size
SOSV
VC Fund
51 United States, India, United Kingdom Seed, Convertible Note, Pre-Seed Biotechnology, Health Care, Software
Sofinnova Partners
VC Fund
28 France, United States, United Kingdom Series A, Series B, Series C Biotechnology, Health Care, Medical $6M–$102M
ARCH Venture Partners
VC Fund
28 United States, China, United Kingdom Series A, Series B, Series C Biotechnology, Health Care, Therapeutics $7.8M–$230M
Alexandria Venture Investments
VC Fund
25 United States, Canada, France Series A, Series B, Seed Biotechnology, Health Care, Therapeutics $2M–$150M
Northpond Ventures
VC Fund
21 United States, United Kingdom, Canada Series A, Series B, Series C Biotechnology, Health Care, Life Science $10M–$100M
Google Ventures
VC Fund
20 United States, United Kingdom, Israel Series A, Series B, Seed Software, Health Care, Biotechnology $1M–$105M
OrbiMed
VC Fund
19 United States, China, Israel Series B, Series A, Series C Biotechnology, Health Care, Medical $10M–$150M
Parkwalk Advisors
VC Fund
18 United Kingdom, United States, Philippines Seed, Series A, Series B Biotechnology, Health Care, Software $982k–$46M
Novartis Venture Fund
VC Fund
18 United States, Switzerland, United Kingdom Series B, Series A, Series C Biotechnology, Health Care, Therapeutics $4.7M–$105M
RA Capital Management
VC Fund
17 United States, United Kingdom, Canada Series B, Series C, Post-IPO Equity Biotechnology, Health Care, Therapeutics $27M–$230M
Bpifrance
VC Fund
16 France, United States, Switzerland Seed, Series A Software, Information Technology, Health Care $658k–$35M
Fifty Years
VC Fund
15 United States, Germany, Canada Seed, Series A, Series B Biotechnology, Health Care, Artificial Intelligence $2M–$91M
DCVC
VC Fund
15 United States, Canada, United Kingdom Seed, Series A, Series B Software, Artificial Intelligence, Machine Learning $1.5M–$130M
Third Rock Ventures
VC Fund
15 United States Series A, Series B, Series C Biotechnology, Health Care, Therapeutics $11M–$150M
Atlas Venture
VC Fund
15 United States, United Kingdom, Canada Series A, Series B, Series C Biotechnology, Health Care, Therapeutics $3.2M–$115M
8VC
VC Fund
15 United States, United Kingdom, Canada Series A, Seed, Series B Software, Health Care, Artificial Intelligence $2.7M–$175M
UK Innovation & Science Seed Fund
VC Fund
15 United Kingdom, United States Seed, Series A Biotechnology, Health Care, Medical $393k–$14M
Oxford Science Enterprises
VC Fund
15 United Kingdom, United States, Finland Seed, Series A, Series B Health Care, Biotechnology, Software $1.3M–$168M
M Ventures
VC Fund
14 United States, United Kingdom, Switzerland Series A, Series B, Seed Biotechnology, Health Care, Therapeutics $2.4M–$100M
Alix Ventures
VC Fund
13 United States Seed, Series A, Pre-Seed Biotechnology, Health Care, Life Science $2M–$70M
SR One
VC Fund
13 United States, United Kingdom, Canada Series A, Series B, Series C Biotechnology, Health Care, Therapeutics $3.7M–$115M
Civilization Ventures
VC Fund
13 United States, United Kingdom, Brazil Seed, Series A, Series B Biotechnology, Health Care, Medical $1.7M–$144M
Novo Holdings
VC Fund
13 United States, Denmark, United Kingdom Series A, Series B, Series C Biotechnology, Health Care, Medical $8M–$125M
Versant Ventures
VC Fund
13 United States, Switzerland, Canada Series A, Series B, Series C Biotechnology, Health Care, Medical $4.7M–$108M
Andreessen Horowitz
VC Fund
12 United States, United Kingdom, Brazil Series A, Seed, Series B Software, Information Technology, Artificial Intelligence $1.5M–$105M
Prox Ventures
VC Fund
12 China, United States, United Kingdom Seed, Series A Medical, Biotechnology, Health Care $1.9M–$28M
Kurma Partners
VC Fund
12 France, Switzerland, Spain Series A, Seed, Series B Health Care, Biotechnology, Medical $2.3M–$80M
Omega Funds
VC Fund
12 United States, Switzerland, United Kingdom Series A, Series B, Series C Biotechnology, Health Care, Therapeutics $14M–$208M
Lux Capital
VC Fund
12 United States, United Kingdom, Canada Series A, Seed, Series B Software, Artificial Intelligence, Health Care $1.8M–$150M
MPM Capital
VC Fund
11 United States, Canada, United Kingdom Series A, Series B, Series C Biotechnology, Health Care, Pharmaceutical $9M–$116M
Hatteras Venture Partners
VC Fund
11 United States, Canada Series A, Series B, Series C Health Care, Biotechnology, Medical $5M–$90M
KdT Ventures
VC Fund
11 United States, India, Canada Seed, Series A, Series B Biotechnology, Health Care, Medical $2.6M–$175M
Horizons Ventures
VC Fund
11 United States, United Kingdom, Canada Series A, Series B, Seed Biotechnology, Software, Artificial Intelligence $1M–$110M
Forbion Capital Partners
VC Fund
11 United States, United Kingdom, The Netherlands Series B, Series A, Series C Biotechnology, Health Care, Medical $12M–$176M
Artis Ventures
VC Fund
11 United States, India, Germany Series A, Series B, Seed Health Care, Biotechnology, Software $2M–$127M
Takeda Ventures
VC Fund
11 United States, United Kingdom, Israel Series A, Series B Biotechnology, Health Care, Therapeutics $10M–$130M
Dementia Discovery Fund
VC Fund
10 United States, United Kingdom, Israel Seed, Series A Biotechnology, Health Care, Therapeutics $5.9M–$77M
HTGF (High-Tech Gruenderfonds)
VC Fund
10 Germany, Switzerland, United States Seed, Series A Software, Biotechnology, Information Technology $909k–$33M
Flagship Pioneering
VC Fund
10 United States, Canada, United Kingdom Series B, Series C, Series A Biotechnology, Health Care, Medical $5.5M–$189M
Sahsen Ventures
VC Fund
10 United States, China, Ghana Series A, Seed Biotechnology, Health Care, Non Profit $1.2M–$81M
F-Prime
VC Fund
10 United States, United Kingdom, China Series A, Series B, Series C Health Care, Biotechnology, Medical $9.2M–$130M
Seventure Partners
VC Fund
10 France, United States, Germany Series A, Series B Biotechnology, Software, Health Care $3.1M–$65M
Casdin Capital
VC Fund
10 United States, China, France Series B, Series A, Series C Biotechnology, Health Care, Therapeutics $10M–$200M
Cormorant Asset Management
VC Fund
10 United States, China, Switzerland Series B, Series C, Series A Biotechnology, Health Care, Medical $16M–$200M
Longwood Fund
VC Fund
10 United States, United Kingdom, Italy Series A, Series B, Series C Biotechnology, Therapeutics, Health Care $15M–$152M
Development Bank of Wales
VC Fund
10 United Kingdom, Australia, United States Seed, Debt Financing Software, Health Care, Biotechnology $18k–$3.7M
Catalio Capital Management
VC Fund
10 United States, Switzerland, Israel Series A, Series B Biotechnology, Health Care, Life Science $18M–$150M
Roche Venture Fund
VC Fund
10 United States, United Kingdom, Spain Series B, Series A, Series C Biotechnology, Health Care, Therapeutics $5M–$105M
Khosla Ventures
VC Fund
10 United States, India, United Kingdom Series A, Series B, Seed Software, Artificial Intelligence, Health Care $1.9M–$100M
Rev1 Ventures
VC Fund
9 United States, Germany Seed, Series A Software, Health Care, Information Technology
Access all 4722 VC funds in Life Science startups.

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Investor list

SOSV
VC Fund · Princeton, New Jersey, United States · 51 investments in Life Science startups, 70 in the past 12 months

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Software
  • Stage:Seed, Convertible Note, Pre-Seed
  • Geography: United States, India, United Kingdom

Investor stats

  • Total investments: 1482
  • Lead/follow: no public data

Portfolio highlights

  • MixRift — MIXRIFT - game developers specialized in Mixed Reality
  • unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
  • Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
Show all investments...

Sofinnova Partners
VC Fund · Paris, Ile-de-France, France · 28 investments in Life Science startups

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Series C
  • Geography: France, United States, United Kingdom

Investor stats

  • Total investments: 298
  • Round size: Series A $6M–$65M; Series B $10M–$102M; Series C $11M–$100M
  • Lead/follow: 46% lead, 54% follow
  • Last fund: Likely still investing — raised $200M in 2023

Portfolio highlights

  • protera — Protera is advancing the science of protein engineering to address some of the most critical problems and opportunities in food, agriculture, the environment and human health. We streamline protein design and development with MADI, our proprietary deep learning algorithm, to predict high value protein products and enzymes with unprecedented speed.Our in-house lab generates small quantities of the new predicted structures to validate their desired performance. Upon lab validation, we collaborate with our clients on next steps to move from pilot to industrial scale production.
  • Bioptimus — Our mission is to build the first universal AI foundation model for biology to fuel breakthrough discoveries and accelerate innovations in biomedicine and beyond.
  • T-Therapeutics — T-Therapeutics is a expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration. .
Show all investments...

ARCH Venture Partners
VC Fund · Chicago, Illinois, United States · 28 investments in Life Science startups

ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Series C
  • Geography: United States, China, United Kingdom

Investor stats

  • Total investments: 377
  • Round size: Series A $7.8M–$200M; Series B $13M–$230M; Series C $15M–$175M
  • Lead/follow: 28% lead, 72% follow
  • Last fund: Likely actively investing — fund raised in 2024

Portfolio highlights

  • Metsera — Metsera operates as a clinical-stage biopharmaceutical company.
  • EGenesis — At eGenesis, we envision a world where transplantation is accessible to all. We develop safe and effective human-compatible organs for transplantation.
  • Protillion Biosciences — Protillion Biosciences is a biotech company commercializing disruptive technology for therapeutic antibody and drug discovery and accelerating biologic research and development productivity.
Show all investments...

Alexandria Venture Investments
VC Fund · Pasadena, California, United States · 25 investments in Life Science startups

Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that aredeveloping transformative new modalities and platforms to meaningfully improve human health.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Seed
  • Geography: United States, Canada, France

Investor stats

  • Total investments: 241
  • Round size: Seed $2M–$31M; Series A $12M–$100M; Series B $22M–$150M
  • Lead/follow: 7% lead, 93% follow

Portfolio highlights

  • miRecule — MiRecule is an early-stage biotechnology company that focuses on developing microRNA-based therapeutics. It features a genomic-based drug development platform that integrates genomic sequencing, expression, and prognostic data from cancer patients. The company was founded in 2016 and headquartered in Gaithersburg, United States.
  • Marvin Health — Marvin is a mental health service for physicians. We're ending the one-size-fits-all approach to teletherapy, helping you to set a teletherapy action plan.
  • Affinia Therapeutics — Affinia Therapeutics is expanding what's possible in adeno-associated virus (AAV) gene therapy today and bringing transformative medicines for people.
Show all investments...

Northpond Ventures
VC Fund · Bethesda, Maryland, United States · 21 investments in Life Science startups

Northpond Ventures is a science-driven venture capital firm headquartered in Bethesda, Maryland. Our mission is to build a better tomorrow. Our investments are focused on life sciences, technology, and affiliated industries.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Life Science
  • Stage:Series A, Series B, Series C
  • Geography: United States, United Kingdom, Canada

Investor stats

  • Total investments: 127
  • Round size: Series A $12M–$68M; Series B $10M–$100M; Series C $22M–$85M
  • Lead/follow: 61% lead, 39% follow

Portfolio highlights

  • QbDVision — QbDVision's digital CMC software for pharma & biotech accelerates drug development by transforming dispersed data & knowledge to process intelligence.
  • Culture Biosciences — Culture Biosciences develops automated bio-reactor that helps biotech companies optimize their manufacturing processes and brings products to market faster. The company also builds automated tools for fermentation. It has a digital bio-manufacturing platform to enable scientists to run, monitor, and analyze bio-reactors faster than traditionalapproaches by robotic sample handling and cloud data monitoring and analysis.Culture Biosciences was founded in 2016 and is headquartered in San Francisco, California.
  • Octave — Octave Bioscience is an early-stage molecular diagnostics company focused on neurodegenerative diseases and conditions. The company was co-founded by Melinda Thomas and William Hagstrom in 2013. Octave Bioscience is headquartered in Menlo Park, California, United States.
Show all investments...

Google Ventures
VC Fund · Mountain View, California, United States · 20 investments in Life Science startups

GV supports innovative founders moving the world forward.

Show more...

Investment focus

  • Industry: Software, Health Care, Biotechnology
  • Stage:Series A, Series B, Seed
  • Geography: United States, United Kingdom, Israel

Investor stats

  • Total investments: 983
  • Round size: Seed $1M–$13M; Series A $5.4M–$86M; Series B $15M–$105M
  • Lead/follow: 32% lead, 68% follow
  • Last fund: May invest from a new fund soon — raised $100M in 2014

Portfolio highlights

  • Allara — Allara is your all-in-one virtual care team for hormonal, metabolic & gynecological conditions such as PCOS and Endometriosis.
  • Smarterer — Individuals and Fortune 500 companies use Smarterer to help close the gap between the skills they have and the skills they need. Their dynamic assessment engine leverages the freshest crowdsourced tests around, to rapidly pinpoint skill level with a credible score. In November 2014, Pluralsight, the global leader in online learning for serioussoftware developers, IT specialists and creative technologists, acquired Smarterer. As the world's largest curated e-learning library for professionals, the company offers instant access to more than 3,500 courses authored by top experts. Smarterer will continue to power crowdsourced assessments for freelancer marketplaces, e-learning providers and enterprise companies anywhere people need to prove their skills to connect with professional opportunities. The Smarterer community has answered over 56 million during 1.7 million test sessions, across hundreds of tests.
  • Merida Biosciences — Merida Biosciences is a new biotech company focused on developing precision treatments, particularly for autoimmune diseases. The company utilize a protein engineering platform to create unique Fc therapeutics, aiming to selectively bind to specific antibodies.
Show all investments...

OrbiMed
VC Fund · New York, New York, United States · 19 investments in Life Science startups

Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series B, Series A, Series C
  • Geography: United States, China, Israel

Investor stats

  • Total investments: 576
  • Round size: Series A $10M–$116M; Series B $24M–$150M; Series C $15M–$131M
  • Lead/follow: 35% lead, 65% follow
  • Last fund: Likely actively investing — fund raised in 2025

Portfolio highlights

  • Sonendo — Sonendo developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The GentleWave® System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment.1,2, 3 Sonendo is the parent company of TDO® Software, the developer of the most widely usedendodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, social media, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System.
  • resTORbio — Restore Beauty - Rethink Bio
  • Caris Life Sciences — Caris fulfills the promise of precision oncology through advanced laboratory testing, including tumor profiling and blood-based cancer diagnostics.
Show all investments...

Parkwalk Advisors
VC Fund · London, England, United Kingdom · 18 investments in Life Science startups

Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Software
  • Stage:Seed, Series A, Series B
  • Geography: United Kingdom, United States, Philippines

Investor stats

  • Total investments: 255
  • Round size: Seed $982k–$4.7M; Series A $1.6M–$13M; Series B $2M–$46M
  • Lead/follow: 29% lead, 71% follow
  • Last fund: Likely still investing — fund raised in 2024

Portfolio highlights

  • Nozzle.ai — Award-winning Amazon analytics tools designed to provide FBA Amazon Sellers with unique customer insights. Try for Free.
  • Phasecraft — Using disruptive theory to unlock the power of quantum computing
  • Echion Technologies — Echion Technologies is a spinout from the University of Cambridge Engineering Department, using proprietary battery active materials to develop next-generation Li-ion batteries.
Show all investments...

Novartis Venture Fund
VC Fund · Basel, Basel-Stadt, Switzerland · 18 investments in Life Science startups

Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series B, Series A, Series C
  • Geography: United States, Switzerland, United Kingdom

Investor stats

  • Total investments: 209
  • Round size: Series A $4.7M–$81M; Series B $11M–$105M; Series C $9M–$75M
  • Lead/follow: 25% lead, 75% follow
  • Last fund: May invest from a new fund soon — raised $200M in 2009

Portfolio highlights

  • Rhygaze — Rhygaze develops a novel gene therapy that targets cone cells to restore vision in patients suffering from diseases causing blindness.
  • Mediar Therapeutics — Mediar Therapeutics is a preclinical stage biotechnology company developing antibody-based therapeutics to halt fibrosis in a variety of organ systems, including lung, liver, kidney, and skin.
  • Amphista Therapeutics — We are purposefully designing the next generation of targeted protein degraders to transform the lives of patients with intractable diseases.
Show all investments...

RA Capital Management
VC Fund · Boston, Massachusetts, United States · 17 investments in Life Science startups

RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series B, Series C, Post-IPO Equity
  • Geography: United States, United Kingdom, Canada

Investor stats

  • Total investments: 425
  • Round size: Series B $27M–$152M; Series C $40M–$200M; Post-IPO Equity $30M–$230M
  • Lead/follow: 37% lead, 63% follow
  • Last fund: Likely actively investing — fund raised in 2025

Portfolio highlights

  • Terrestrial Bio — Vaxess engineers novel technologies that uniquely engage the human immune system, enabling improved efficacy and simplified access for vaccines and therapeutics.
  • Capstan Therapeutics — Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.
  • ILiAD Biotechnologies
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Bpifrance
VC Fund · Maisons-alfort, Ile-de-France, France · 16 investments in Life Science startups

Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.

Show more...

Investment focus

  • Industry: Software, Information Technology, Health Care
  • Stage:Seed, Series A
  • Geography: France, United States, Switzerland

Investor stats

  • Total investments: 988
  • Round size: Seed $658k–$6.4M; Series A $2.5M–$35M
  • Lead/follow: 22% lead, 78% follow
  • Last fund: Likely actively investing — fund raised in 2025

Portfolio highlights

  • May Health — May Health is developing a modern treatment - Ovarian Rebalancing - designed to restore ovulation for people with polycystic ovary syndrome.
  • Callyope — Callyope is building the first speech-based foundational model to monitor mental health symptoms through low-touch smartphone interactions.
  • Smile Wanted Group — Spot the most valuable inventory on premium websites and provide guarantees of performance to advertisers. Reach +500M users /month globally.
Show all investments...

Fifty Years
VC Fund · San Francisco, California, United States · 15 investments in Life Science startups

WE BACK HEROES using technology to solve the world's biggest problems

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Artificial Intelligence
  • Stage:Seed, Series A, Series B
  • Geography: United States, Germany, Canada

Investor stats

  • Total investments: 162
  • Round size: Seed $2M–$15M; Series A $8.5M–$40M; Series B $16M–$91M
  • Lead/follow: 18% lead, 82% follow
  • Last fund: Likely still investing — raised $90M in 2021

Portfolio highlights

  • Farcast — Unlocking satellite internet capacity through user terminal innovation
  • Solugen — Solugen's mission is to decarbonize the chemicals industry. Solugen combines synthetic biology with metal catalysis to make carbon negative chemicals at scale.Solugen's patented approach takes advantage of bio-inspired reactions to use plant material as a low-cost feedstock to produce novel products cost-competitive with thecompetition.
  • Valence Discovery — Empowering drug discovery scientists with the latest advances in AI-enabled drug design
Show all investments...

DCVC
VC Fund · San Francisco, California, United States · 15 investments in Life Science startups

We are deep tech venture capital.

Show more...

Investment focus

  • Industry: Software, Artificial Intelligence, Machine Learning
  • Stage:Seed, Series A, Series B
  • Geography: United States, Canada, United Kingdom

Investor stats

  • Total investments: 381
  • Round size: Seed $1.5M–$10M; Series A $5.7M–$50M; Series B $15M–$130M
  • Lead/follow: 24% lead, 76% follow
  • Last fund: Likely still investing — raised $1B in 2023

Portfolio highlights

  • Twelve — Twelve is a carbon transformation company converting captured carbon dioxide into valuable chemicals, fuels, and other essential products. Their technology eliminates emissions by turning CO2 into essential products that are made from fossil fuels. They specialize in the fields of CO2 electrocatalysis and electrochemical reactor design.
  • ZwitterCo — ZwitterCo is revolutionizing water & wastewater treatment with cutting-edge membrane technology, along with providing sustainable, high-efficiency solutions.
  • Petra — Petra is a robotics company that can bury utilities in the most difficult and disaster-prone areas on earth.
Show all investments...

Third Rock Ventures
VC Fund · Boston, Massachusetts, United States · 15 investments in Life Science startups

Third Rock Ventures invests in transformational life science companies that show high growth potential and are well-positioned to make a difference in the marketplace. Third Rock Ventures believes in the companies we start and makes significant initial investments, which are frequently supplemented by strategic collaborations, to help our firmsprogress in life-changing medicines, technologies, and diagnostics.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Series C
  • Geography: United States

Investor stats

  • Total investments: 144
  • Round size: Series A $17M–$102M; Series B $11M–$150M; Series C $14M–$146M
  • Lead/follow: 44% lead, 56% follow
  • Last fund: Likely still investing — fund raised in 2022

Portfolio highlights

  • CytomX Therapeutics — CytomX Therapeutics is a biotechnology company that focuses on developing proteolytically-activated antibodies. Their mission, alone and with the help of partners, is to provide patients with more effective and less toxic therapies for severe illnesses such as cancer and inflammatory diseases.
  • Jounce Therapeutics — Concentra is a biosciences company.
  • Syremis Therapeutics
Show all investments...

Atlas Venture
VC Fund · Cambridge, Massachusetts, United States · 15 investments in Life Science startups

Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on compelling opportunities to build scalable businesses and realize value.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Series C
  • Geography: United States, United Kingdom, Canada

Investor stats

  • Total investments: 415
  • Round size: Series A $3.2M–$70M; Series B $8M–$115M; Series C $6M–$95M
  • Lead/follow: 28% lead, 72% follow
  • Last fund: Likely still investing — fund raised in 2022

Portfolio highlights

  • Grockit — Grockit is a pioneering online social learning company. Grockit has proven that people learn more, faster through combining social learning mechanics and multi-media learning content to help people teach and learn from others. Grockit.com offers Test Prep services for GMAT, IIM CAT, LSAT, GRE, ACT, SAT and AP Calculus and AP History tests.Grockit has built a social learning test prep platform for license and direct-to-consumer products. Florida Virtual Schools, KIPP Schools, Georgetown University and other schools have deployed Grockit services.
  • Judo Bio — Judo Bio is pioneering oligonucleotide medicines delivered to the kidney, opening the way for new treatments for systemic and renal diseases.
  • Remix Therapeutics — Remix Therapeutics is a biotechnology company that develops novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways.
Show all investments...

8VC
VC Fund · San Francisco, California, United States · 15 investments in Life Science startups

8VC is a technology and life sciences investment firm that partners with founders to develop transformational technologies. The firm focuses on creating long-term economic and societal value through its investments across various sectors, including healthcare and logistics.

Show more...

Investment focus

  • Industry: Software, Health Care, Artificial Intelligence
  • Stage:Series A, Seed, Series B
  • Geography: United States, United Kingdom, Canada

Investor stats

  • Total investments: 461
  • Round size: Seed $2.7M–$12M; Series A $8M–$55M; Series B $16M–$175M
  • Lead/follow: 34% lead, 66% follow

Portfolio highlights

  • Latus Bio — Latus Bio focuses on developing innovative gene therapy candidates using precision delivery to enhance the lives of patients. Latus identified proprietary AAV capsids for clinical use. The company plans to administer low doses of its product candidates, aiming to improve clinical safety and manufacturing.
  • DataHub — DataHub Core is the #1 open source platform with a uniquely scalable and extensible metadata graph supporting manual and automated data management. DataHub Cloud is an enterprise-ready SaaS solution providing a fully-managed service of DataHub Core with additional AI-powered capabilities in discovery, observability, and governance to accelerateproduction-readiness of AI and data assets.
  • Flywheel.io — Flywheel is a data management and analysis platform built specifically for scientists and the researcher's workflow. They empower research momentum by focusing on data and medical image capture, content management, scientific computation, and collaboration. With reproducible research in mind, they combine open-source methods from topuniversities, a modern web user interface, and an extensible compute engine based on containerization technology. The result is a software platform to accelerate discovery and help researchers do science, not IT.Flywheel accelerates new scientific discoveries in life-science, biotech, and academic imaging research through cloud-scale collaboration. As a result, imaging researchers are able to avoid innovation bottlenecks, and accelerate discovery by doing more science, and less IT.
Show all investments...

UK Innovation & Science Seed Fund
VC Fund · Harwell, Oxfordshire, United Kingdom · 15 investments in Life Science startups

UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Seed, Series A
  • Geography: United Kingdom, United States

Investor stats

  • Total investments: 130
  • Round size: Seed $393k–$5.9M; Series A $2.9M–$14M
  • Lead/follow: 33% lead, 67% follow
  • Last fund: May invest from a new fund soon — last raise in 2014

Portfolio highlights

  • NanoSyrinx — NanoSyrinx is an award-winning, discovery stage biotechnology company based in the UK. We are using synthetic biology approaches to develop protein nanosyringes as a completely novel modality for intracellular delivery of protein and peptide biologic drugs.
  • Presymptom Health — Enabling Early Diagnosis for better infection & sepsis care. With faster, more accurate testing. Presymptom Health is a medtech company developing a portfolio of patented diagnostic tests that are both faster and more reliable than those available today. Accelerate diagnosis. Address antimicrobial resistance.
  • Pencil Biosciences — Pencil Biosciences is pioneering the next generation of gene editing. We are developing a fully synthetic, RNA-guided platform designed to overcome the limitations of current technologies.
Show all investments...

Oxford Science Enterprises
VC Fund · Oxford, Oxfordshire, United Kingdom · 15 investments in Life Science startups

Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Software
  • Stage:Seed, Series A, Series B
  • Geography: United Kingdom, United States, Finland

Investor stats

  • Total investments: 160
  • Round size: Seed $1.3M–$10M; Series A $5M–$46M; Series B $8.5M–$168M
  • Lead/follow: 37% lead, 63% follow
  • Last fund: Likely still investing — raised $327M in 2022

Portfolio highlights

  • Navenio — Intelligent Location-Based Workforce Solutions A tech-light approach to empowering hospital care teams to proactively drive the orchestration of care.
  • Pepgen — PepGen empowers nucleic acid therapeutics to go the distance. PepGen's ambition is to unlock the potential of nucleic acid therapeutics by leveraging the drug delivery capabilities of their innovative product engine. PepGen's initial focus is on the application of this technology to the efficacious delivery of antisense oligonucleotides,and they are advancing novel conjugate therapeutics to the clinic.
  • Caristo Diagnostics — Our AI powered CaRi-Heart technology uncovers coronary inflammation, atherosclerosis, and plaque progression on cardiac CT. Learn more about our award-winning technology
Show all investments...

M Ventures
VC Fund · Amsterdam, Noord-Holland, The Netherlands · 14 investments in Life Science startups

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Seed
  • Geography: United States, United Kingdom, Switzerland

Investor stats

  • Total investments: 163
  • Round size: Seed $2.4M–$21M; Series A $5.2M–$45M; Series B $15M–$100M
  • Lead/follow: 39% lead, 61% follow

Portfolio highlights

  • CellFE — We transform the way cell therapies are manufactured to enable affordable advanced treatments for all.
  • UNISERS — Developing solutions for Universal Contamination Analysis. Working with cutting edge technologies to revolutionize contamination control.
  • Polaris Electro-Optics — Polaris Electro-Optics empowers integrated photonics for communications and computation.
Show all investments...

Alix Ventures
VC Fund · San Francisco, California, United States · 13 investments in Life Science startups

Supporting early stage Life Science startups driving patient impact. Born from our collective experience as founders, we set out to build the fund we wanted to raise from....

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Life Science
  • Stage:Seed, Series A, Pre-Seed
  • Geography: United States

Investor stats

  • Total investments: 22
  • Round size: Seed $2M–$12M; Pre-Seed $2.7M–$2.7M; Series A $12M–$70M
  • Lead/follow: 14% lead, 86% follow

Portfolio highlights

  • Elegen — Skip cloning with the only entirely cell-free DNA synthesis provider. Sequences up to 7 kb. Error rates as low as 1:70,000/bp. Manufactured in USA, NGS-verified and shipped globally in as few business days.
  • iOrganBio — iOrganBio is a pioneering cell production platform that uses CellForge to facilitate the intelligent manufacturing of human cells and organoids.
  • Galatea Bio — Galatea Bio, a US-based biotechnology company was founder by Carlos Bustamante, Nicholas Katsanis and Alexander Ioannidis. Our mission is to drive groundbreaking discoveries in healthcare by pairing genetic diversity with cutting-edge data analytics. Our passion is fueled by a focus on populations historically underrepresented in genetics research.We achieve this by leveraging our world-class clinical network and biobank, cutting-edge algorithms, and innovative analyses to discover and validate new tests, treatments, and cures that will improve the lives of all.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
SR One
VC Fund · Cambridge, Massachusetts, United States · 13 investments in Life Science startups

SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Series C
  • Geography: United States, United Kingdom, Canada

Investor stats

  • Total investments: 182
  • Round size: Series A $3.7M–$87M; Series B $15M–$114M; Series C $22M–$115M
  • Lead/follow: 30% lead, 70% follow
  • Last fund: Likely still investing — fund raised in 2023

Portfolio highlights

  • Turning Point Therapeutics — The Investor Relations website contains information about Turning Point Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
  • Spero Therapeutics — Spero Therapeutics is developing first in class therapeutics for treatment of Gram-negative infections. The company leverages a top-tier chemistry and microbiology team, an efficient virtual approach to drug development, and a focus on high potential, novel mechanisms to fill the unmet need for early stage therapeutics targeting serious bacterialinfections. Spero’s lead program addresses a novel target driving virulence and persistence of Pseudomonas Aeruginosa infections and other Gram-negative pathogens. The company was founded by Atlas Venture, with financing from SR One and the Partners Innovation Fund.
  • Constellation Pharmaceuticals — Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science which is focused on selective regulators of epigenetic function, which are critical to controlling gene expression.
Show all investments...

Civilization Ventures
VC Fund · San Francisco, California, United States · 13 investments in Life Science startups

DIGITAL HEALTH / AI DIGITAL HEALTH / AI GENE / CELL THERAPIES NASDAQ: RCKT GENE / CELL THERAPIES NASDAQ: RCKT GENOMICS / DIAGNOSTICS GENOMICS / DIAGNOSTICS SYNTHETIC

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Seed, Series A, Series B
  • Geography: United States, United Kingdom, Brazil

Investor stats

  • Total investments: 71
  • Round size: Seed $1.7M–$16M; Series A $8M–$28M; Series B $26M–$144M
  • Lead/follow: 3% lead, 97% follow

Portfolio highlights

  • OxCan — Enabling curative cancer treatment through early detection
  • Wyndly — Retrain your allergies through sublingual (under-the-tongue) treatment plans. Virtual appointments. Treatment delivered. Get started after your first consult with a board-certified doctor for $49.99.
  • Foresight Diagnostics — We develop innovative diagnostics to advance decision-making in oncology drug development and patient care.
Show all investments...

Novo Holdings
VC Fund · Hellerup, Hovedstaden, Denmark · 13 investments in Life Science startups

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Series C
  • Geography: United States, Denmark, United Kingdom

Investor stats

  • Total investments: 313
  • Round size: Series A $8M–$100M; Series B $12M–$125M; Series C $30M–$115M
  • Lead/follow: 39% lead, 61% follow
  • Last fund: May invest from a new fund soon — raised $165M in 2018

Portfolio highlights

  • Hillstar Bio — Hillstar Bio is pioneering precision immunotherapies that target and deplete pathogenic immune cells, aiming to reset the immune system and transform treatment for autoimmune diseases.
  • Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
  • Bolt Biotherapeutics — Bolt is leveraging the immune system for a better way to treat cancer. Our approach works with a person's body, not against it.
Show all investments...

Versant Ventures
VC Fund · Menlo Park, California, United States · 13 investments in Life Science startups

Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Series C
  • Geography: United States, Switzerland, Canada

Investor stats

  • Total investments: 278
  • Round size: Series A $4.7M–$80M; Series B $10M–$105M; Series C $12M–$108M
  • Lead/follow: 28% lead, 72% follow
  • Last fund: Likely still investing — fund raised in 2023

Portfolio highlights

  • Achaogen — Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. The company's most advanced drug candidate, ACHN-490, has demonstrated a positive safety and dosing profile in Phase 1 clinical testing and displayed broad spectrumefficacy in preclinical studies against systemic infections caused by multi-drug resistant (MDR) Gram-negative bacteria (e.g., E. coli, K. pneumoniae, and P. aeruginosa) and MRSA. In addition, the company is pursuing preclinical programs in several other areas of interest to combat the global emergence of bacterial resistance.
  • Passage Bio — Passage Bio, a genetic medicines company, is changing the future of CNS disorders and transforming the lives of patients and their families.
  • Dayra Therapeutics
Show all investments...

Andreessen Horowitz
VC Fund · Menlo Park, California, United States · 12 investments in Life Science startups

Andreessen Horowitz (a16z) is a venture capital firm in Silicon Valley, California, investing in bold founders, innovators, and entrepreneurs building the future through technology.

Show more...

Investment focus

  • Industry: Software, Information Technology, Artificial Intelligence
  • Stage:Series A, Seed, Series B
  • Geography: United States, United Kingdom, Brazil

Investor stats

  • Total investments: 1577
  • Round size: Seed $1.5M–$15M; Series A $8.8M–$52M; Series B $16M–$105M
  • Lead/follow: 47% lead, 53% follow
  • Last fund: Likely actively investing — fund raised in 2025

Portfolio highlights

  • OpenGov — OpenGov provides software and professional services purpose-built for local government to move communities forward.
  • Shapeways — Shapeways is the #1 online 3D printing service company. Working with over a million customers since 2007 - Get 3D products and parts delivered to over 100 countries.
  • Udio — Discover, create, and share music with the world. Use the latest technology to create AI music in seconds.
Show all investments...

Prox Ventures
VC Fund · Shanghai, Shanghai, China · 12 investments in Life Science startups

Proxima Ventures focuses in the healthcare industry, supporting outstanding enterprises with innovative technologies or service models that have tremendous potential.They manage multiple funds in RMB and US dollar, covering from seed to growth stages. Their team members with multidisciplinary backgrounds and resourceful networks, have many yearsof remarkable venture capital experience and achievements. They believe that active and effective collaboration with entrepreneurs will make substantial economic returns while bring meaningful improvements in public health.

Show more...

Investment focus

  • Industry: Medical, Biotechnology, Health Care
  • Stage:Seed, Series A
  • Geography: China, United States, United Kingdom

Investor stats

  • Total investments: 72
  • Round size: Seed $1.9M–$5.6M; Series A $2.8M–$28M
  • Lead/follow: 15% lead, 85% follow

Portfolio highlights

  • Brise Pharma — Brise Pharma operates in the scientific research and technical service industry.
  • Tuanxiang Pharmaceutical — Tuanxiang Pharmaceutical is an innovative drug research and development company that combines traditional new drug research and development with the use of the world's leading unique phase separation technology.
  • Rapafusyn Pharmaceuticals — Rapafuysn is pioneering RapaGlues - a modality of non-degrading molecular glues that addresses hard-to-drug targets.
Show all investments...

Kurma Partners
VC Fund · Paris, Ile-de-France, France · 12 investments in Life Science startups

Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovationsin Europe, particularly through links with many institutes. research and prestigious hospitals.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Series A, Seed, Series B
  • Geography: France, Switzerland, Spain

Investor stats

  • Total investments: 128
  • Round size: Seed $2.3M–$13M; Series A $3.8M–$74M; Series B $8.8M–$80M
  • Lead/follow: 50% lead, 50% follow
  • Last fund: Likely actively investing — fund raised in 2024

Portfolio highlights

  • Medlumics — Medlumics is a medical device start-up born in 2009 from a compromise with improving human living standards by means of technology.
  • Vico Therapeutics — Pioneering RNA-based science to target the root cause of rare genetic neurological diseases VO659: The first clinical candidate directly targeting the CAG repea
  • Synendos Therapeutics — Synendos Therapeutics is a biopharmaceutical company that aims to develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of natural functioning of the brain.
Show all investments...

Omega Funds
VC Fund · Boston, Massachusetts, United States · 12 investments in Life Science startups

We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Series C
  • Geography: United States, Switzerland, United Kingdom

Investor stats

  • Total investments: 140
  • Round size: Series A $16M–$187M; Series B $35M–$162M; Series C $14M–$208M
  • Lead/follow: 24% lead, 76% follow
  • Last fund: Likely still investing — fund raised in 2023

Portfolio highlights

  • Andrew Alliance — OneLab is laboratory software to design and execute liquid handling protocols. Pipette+ for manual liquid handling pipetting and Andrew+ the pipetting robot
  • Aerium Therapeutics — Aerium is building a company dedicated to the discovery & development of antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic & pandemic threats.
  • Scorpion Therapeutics — We are developing drugs specifically designed to interact with validated cancer targets with greater selectivity and optimized pharmaceutical properties to improve their safety and efficacy.
Show all investments...

Lux Capital
VC Fund · New York, New York, United States · 12 investments in Life Science startups

Lux Capital manages over $5 billion in assets focused on founding, seed, early-stage, and growth investments at the intersection of technology and the sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high-growth sectors. Its investment team has built over 20 companies from scratch. Lux's investmentstrategy ensures portfolio companies are better connected, have a deeper insight, and command industry leadership faster than their competitors.

Show more...

Investment focus

  • Industry: Software, Artificial Intelligence, Health Care
  • Stage:Series A, Seed, Series B
  • Geography: United States, United Kingdom, Canada

Investor stats

  • Total investments: 495
  • Round size: Seed $1.8M–$30M; Series A $7M–$60M; Series B $13M–$150M
  • Lead/follow: 31% lead, 69% follow
  • Last fund: May invest from a new fund soon — raised $100M in 2007

Portfolio highlights

  • Primer — Primer makes powerful mission-ready AI software designed to work in your environment, on your data. We help national security teams sift through massive unstructured data sets to find the needle in the haystack, understand and visualize their data, and act collaboratively. Our mission is to empower decisions that can be defended, and acted upon confidently.
  • Summer Health — Get answers from an expert, board-certified pediatricians in 15 minutes. From child health to development, Summer Health gets you answers any time, day or night.
  • Physical Intelligence — Physical Intelligence is bringing general-purpose AI into the physical world.
Show all investments...

MPM Capital
VC Fund · Cambridge, Massachusetts, United States · 11 investments in Life Science startups

Powering Breakthroughs in Life Sciences

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Pharmaceutical
  • Stage:Series A, Series B, Series C
  • Geography: United States, Canada, United Kingdom

Investor stats

  • Total investments: 224
  • Round size: Series A $9M–$84M; Series B $20M–$116M; Series C $12M–$100M
  • Lead/follow: 35% lead, 65% follow
  • Last fund: Likely still investing — raised $850M in 2021

Portfolio highlights

  • Epigenomics — Epigenomics is a molecular diagnostics company focusing on the development and commercialization of in vitro diagnostic tests for cancer. Its cancer diagnostic tests aim at finding cancer at early stages before symptoms occur and are carried out conveniently on body fluids such as blood plasma. These tests potentially address millions ofindividuals in each of the major markets such as the United States, Europe, and Japan and provide product opportunities each with peak sales potentials of several hundred millions of euros for diagnostics companies worldwide. Its lead test development program is in colorectal cancer. Further test are in development for lung and prostate cancer. Each of its products in development addresses either mass markets or high-value niches. While some of them lend themselves to partnering with established diagnostics industry players, others can be commercialized effectively by Epigenomics itself. The concept of its diagnostic tests in development relies on detecting differences in DNA methylation patterns between healthy and sick individuals or between subgroups of patients for disease classification.
  • Umoja Biopharma — Pioneering immunotherapy by reprogramming T cells in vivo to target cancer cells.
  • Syndax Pharmaceuticals — Syndax Pharmaceuticals is a clinical-stage pharmaceutical company that focuses on an HDAC inhibitor for solid tumors and hematological tumors. It offers therapies to treat solid tumors and lung, breast, and hematological cancer. The company is developing axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor,in development for chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor.Syndax Pharmaceuticals pipeline includes and SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, in development for the treatment of patients with MLLr and NPM1 acute leukemias.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Hatteras Venture Partners
VC Fund · Durham, North Carolina, United States · 11 investments in Life Science startups

Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to buildingsuccessful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Series A, Series B, Series C
  • Geography: United States, Canada

Investor stats

  • Total investments: 128
  • Round size: Series A $5.2M–$41M; Series B $5M–$90M; Series C $6M–$47M
  • Lead/follow: 37% lead, 63% follow
  • Last fund: Likely still investing — fund raised in 2023

Portfolio highlights

  • Ribometrix — The Next Frontier of Drug Discovery
  • Contego Medical — Better Outcomes. Simplified. Neurovascular Peripheral Vascular Neurovascular
  • G1 Therapeutics — G1 Therapeutics is a clinical-stage company developing novel cancer therapies. It was founded in 2008 by Drs. Norman Sharpless and Kwok-Kin Wong to capitalize on discoveries made and patented by Dr. Sharpless’ lab at the University of North Carolina at Chapel Hill, and subsequently licensed to G1 Therapeutics. Trilaciclib is an investigationaltherapy designed to improve outcomes for people with cancer who are treated with chemotherapy. G1 is also advancing rintodestrant, a potential best-in-class oral selective estrogen receptor degrader, or SERD, for the treatment of ER+ breast cancer.
Show all investments...

KdT Ventures
VC Fund · Austin, Texas, United States · 11 investments in Life Science startups

KdT Ventures is the standard for early-stage frontier science investing.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Seed, Series A, Series B
  • Geography: United States, India, Canada

Investor stats

  • Total investments: 88
  • Round size: Seed $2.6M–$13M; Series A $8.5M–$70M; Series B $25M–$175M
  • Lead/follow: 9% lead, 91% follow
  • Last fund: Likely still investing — raised $80M in 2022

Portfolio highlights

  • Elegen — Skip cloning with the only entirely cell-free DNA synthesis provider. Sequences up to 7 kb. Error rates as low as 1:70,000/bp. Manufactured in USA, NGS-verified and shipped globally in as few business days.
  • Checkerspot — A biology-driven platform creating specialized lipids from fermentation
  • Tierra Biosciences — Speed, scale and simplicity with protein synthesis on-demand. Discover your portal to thousands of custom proteins. Get testable material with a single input.
Show all investments...

Horizons Ventures
VC Fund · Hong Kong, Hong Kong Island, Hong Kong · 11 investments in Life Science startups

Investing in the deep science and technology that can propel humanity towards a radically better future.

Show more...

Investment focus

  • Industry: Biotechnology, Software, Artificial Intelligence
  • Stage:Series A, Series B, Seed
  • Geography: United States, United Kingdom, Canada

Investor stats

  • Total investments: 250
  • Round size: Seed $1M–$11M; Series A $6.2M–$50M; Series B $8M–$110M
  • Lead/follow: 44% lead, 56% follow

Portfolio highlights

  • Scopely — Scopely is a global interactive entertainment and mobile-first games company, home to many top-grossing, award-winning franchises including “Star Trek™ Fleet Command,” “MARVEL Strike Force,” “Scrabble® GO,” “WWE Champions” and “Yahtzee® With Buddies,” among others. Scopely creates, publishes and live-operates immersive games that empower adirected-by-consumer™ experience. Founded in 2011, Scopely is fueled by a world-class team and a proprietary technology platform Playgami that supports one of the most diversified portfolios in the mobile games industry. Recognized multiple times as one of Fast Company’s “World’s Most Innovative Companies,” Scopely is a multi-billion-dollar business due to its ability to create long-lasting game experiences that players enjoy for years. Scopely has global operations across 17 markets (Asia-Pacific - Bangalore, Seoul, Shanghai, Singapore, Tokyo; EMEA - Barcelona, Dublin, Helsinki, Kyiv, London, Seville, Tel Aviv; North America - Boston, Boulder, Culver City, Mountain View, San Francisco), with additional game studio partners across four continents. For more information, visit www.scopely.com.
  • Synthace — The Synthace Experiment Platform lets you design powerful experiments, run them in your lab, & gather automatically structured datasets. No code necessary.
  • Amper Music — Amper is an AI music composition company that develops tools for content creators of all kinds. Learn about our new enterprise platform, Score, as well as our creator API.
Show all investments...

Forbion Capital Partners
VC Fund · Naarden, Noord-Holland, The Netherlands · 11 investments in Life Science startups

Impacting the future of medicine.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series B, Series A, Series C
  • Geography: United States, United Kingdom, The Netherlands

Investor stats

  • Total investments: 171
  • Round size: Series A $14M–$176M; Series B $12M–$155M; Series C $12M–$113M
  • Lead/follow: 50% lead, 50% follow
  • Last fund: Likely actively investing — fund raised in 2024

Portfolio highlights

  • F2G — F2G is a biopharmaceutical company developing novel therapies for life-threatening fungal infections.
  • Noema Pharma — DRIVING BETTER OUTCOMES Advancing therapeutics designed to deliver superior clinical benefit across both orphan and broader neurology indications Who we are ...
  • Orbis Medicines — Orbis Medicines is a novel macrocyclic chemistry and computational platform for high-throughput drug discovery.
Show all investments...

Artis Ventures
VC Fund · San Francisco, California, United States · 11 investments in Life Science startups

Artis Ventures has spent over a decade backing bold teams who take the hard path, building market-defining companies to re-shape, re-invent, and re-make industries.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Software
  • Stage:Series A, Series B, Seed
  • Geography: United States, India, Germany

Investor stats

  • Total investments: 139
  • Round size: Seed $2M–$40M; Series A $4M–$55M; Series B $20M–$127M
  • Lead/follow: 37% lead, 63% follow

Portfolio highlights

  • ChefsFeed — Elevate your taste with mouth-watering recipes and award-winning lifestyle shows. Stream for free or join Tastemade+ for unlimited, ad-free access.
  • Practice Fusion — 'Deliver better care more efficiently with the #1 electronic health record. Our industry-leading EHR was developed with feedback from over 150,000 professionals.'
  • Second Front Systems — The continuous accreditation and deployment of commercial software is crucial for U.S. national security missions. With Second Front Systems' Game Warden platform, you'll be achieving exactly that.
Show all investments...

Takeda Ventures
VC Fund · San Diego, California, United States · 11 investments in Life Science startups

Takeda Ventures, Inc. (TVI) is the corporate investment arm of Takeda Pharmaceutical Company Limited (TPC). TVI was founded in 2001 and invests in current and future areas of interest for TPC. They are based alongside Takeda’s R&D sites in Cambridge, MA, and San Diego, CA. As a strategic investor, TVI aims to provide support and guidance toentrepreneurs and early-stage companies driving concepts through clinical proof of concept. They also strive to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources. Their goal is to build a portfolio of strategic investments, with an immediate emphasis on oncology, gastroenterology, neuroscience, and rare diseases.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B
  • Geography: United States, United Kingdom, Israel

Investor stats

  • Total investments: 103
  • Round size: Series A $10M–$58M; Series B $20M–$130M
  • Lead/follow: 18% lead, 82% follow

Portfolio highlights

  • Degron Therapeutics — Degron Therapeutics is a leading platform company in discovery of molecular glue degraders for cancer treatment.
  • Accipiter Biosciences — Accipiter Biosciences is a biotechnology company.
  • Harness Therapeutics — Transine Therapeutics is a private biotechnology company focused on the development of a novel class of therapeutic RNAs that can upregulate protein expression with an unprecedented level of control and specificity: the SINEUPs®. The company's pioneering technology is expected to offer an entirely unique mechanism of action for currentlyhard-to-treat diseases by massively extending the druggable proteome and allowing it to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies.
Show all investments...

Dementia Discovery Fund
VC Fund · London, England, United Kingdom · 10 investments in Life Science startups

SV Health Investors is a specialist healthcare fund manager, investing across multiple stages and sectors. Our goal is to transform healthcare one investment at a time.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Seed, Series A
  • Geography: United States, United Kingdom, Israel

Investor stats

  • Total investments: 49
  • Round size: Seed $5.9M–$20M; Series A $7M–$77M
  • Lead/follow: 41% lead, 59% follow
  • Last fund: May invest from a new fund soon — raised $337M in 2018

Portfolio highlights

  • QurAlis — QurAlis is a operator of a biotechnology company intended to discover and develop potential precision therapeutics for amyotrophic lateral sclerosis (ALS). The company focuses on the link between genetics and disease in ALS and other neurological diseases, enabling doctors to successfully treat ALS .
  • Nitrase Therapeutics — Nitrase Therapeutics is a platform company developing drugs against a newly identified class of enzymes called Nitrases, initially targeting Parkinson’s disease. The therapies that Nitrome is developing will target these enzymes and potentially help slow or halt the progression of diseases such as Parkinson’s. While the initial focus is onParkinson's disease, the company aims to expand its proprietary platform to include other disease indications.
  • Violet Therapeutics — Violet Therapeutics is a healthcare company that operates in stealth mode.
Show all investments...

HTGF (High-Tech Gruenderfonds)
VC Fund · Bonn, Nordrhein-Westfalen, Germany · 10 investments in Life Science startups

High-Tech Grunderfonds finances startups with growth potential. Its team of investment managers supports young companies with expertise, entrepreneurial spirit, and passion. The company focuses in the fields of digital tech, industrial tech, life sciences, chemistry, and related business areas. It also focuses on financial services in varioussectors.

Show more...

Investment focus

  • Industry: Software, Biotechnology, Information Technology
  • Stage:Seed, Series A
  • Geography: Germany, Switzerland, United States

Investor stats

  • Total investments: 542
  • Round size: Seed $909k–$6.5M; Series A $3M–$33M
  • Lead/follow: 35% lead, 65% follow
  • Last fund: Likely still investing — raised $522M in 2022

Portfolio highlights

  • Sdui — Sdui is the solution for mobile communication in schools. With amazingly easy features for messaging, timetables and a wide range of third party integrations, the app digitizes processes and reduces administrative effort. Within two years, Sdui has reached hundreds of institutions and grown a serious reputation in the educational market.
  • envelio — We are driving forward the energy transition with our smart grid solutions for grid operators. Get information now and plan smart!
  • VisioLab — Instantly scan products for self-checkout, using the iPad camera - no barcodes needed. Designed for speed, simplicity and human centricity.
Show all investments...

Flagship Pioneering
VC Fund · Cambridge, Massachusetts, United States · 10 investments in Life Science startups

We create breakthroughs in human health and sustainability and build bioplatform companies . Companies founded

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series B, Series C, Series A
  • Geography: United States, Canada, United Kingdom

Investor stats

  • Total investments: 190
  • Round size: Series A $5.5M–$75M; Series B $10M–$189M; Series C $12M–$123M
  • Lead/follow: 37% lead, 63% follow
  • Last fund: Likely actively investing — fund raised in 2024

Portfolio highlights

  • Montai Therapeutics — Harnessing untapped diverse chemistry with AI-enabled drug discovery to develop breakthrough small molecule medicines for chronic disease.
  • Quotient Therapeutics — Discover how Quotient is pioneering a new field of genetics with somatic genomics to unveil a universe of genetic information and develop new therapies.
  • Ampersand Biomedicines — Ampersand is enabling potent mechanisms to treat disease by creating and programming therapeutics that are more efficacious, without compromising on safety or tolerability.
Show all investments...

Sahsen Ventures
VC Fund · Seattle, Washington, United States · 10 investments in Life Science startups

Sahsen Ventures is a venture capital firm making investments in for-profit and nonprofit organizations with an emphasis on technology and biotechnology. It was established in 2016 and is based in Seattle, Washington.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Non Profit
  • Stage:Series A, Seed
  • Geography: United States, China, Ghana

Investor stats

  • Total investments: 85
  • Round size: Seed $1.2M–$25M; Series A $13M–$81M
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Outpace Bio — Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
  • Synthesize Bio — Deep biomedical data is the key to unlocking discoveries and creating therapies. Synthesize Bio uses AI to reduce data collection and analysis from months to minutes for a fraction of the cost in time, personnel, and materials.
  • Archon Biosciences — Archon is a biotechnology firm that creates computationally engineered proteins to unleash potent therapeutic targets beyond the grasp of current methods and improve disease management.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
F-Prime
VC Fund · Cambridge, Massachusetts, United States · 10 investments in Life Science startups

F-Prime Capital is a global venture capital firm investing in healthcare and technology, with a heritage that spans four decades.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Series A, Series B, Series C
  • Geography: United States, United Kingdom, China

Investor stats

  • Total investments: 410
  • Round size: Series A $9.2M–$87M; Series B $16M–$130M; Series C $22M–$115M
  • Lead/follow: 27% lead, 73% follow

Portfolio highlights

  • SILQ — Bringing visibility to brands by customizing sourcing and shipping on everything that you need for your business.
  • Deal Engine — Deal Engine is a travel solutions software company that reduces corporate travel expenditure ensuring saving on a flight itinerary.
  • RightHand Robotics — RightHand Robotics offers advanced robotic piece-picking technology for efficient and predictable order fulfillment. Contact us today to learn how.
Show all investments...

Seventure Partners
VC Fund · Paris, Ile-de-France, France · 10 investments in Life Science startups

Seventure Partners is a French venture capital firm targeting in Tech/Digital and Life Sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with € 1 billion undermanagement as of December 31, 2023. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.The different funds/verticals on which Seventure Partners are focusing on today: - Life Sciences : Biotech, Healthcare, Nutrition - Tech/Digital : B2B SaaS, Fintech, Retailtech, Cybersecurity - Sports & Wellbeing - Blue Economy

Show more...

Investment focus

  • Industry: Biotechnology, Software, Health Care
  • Stage:Series A, Series B
  • Geography: France, United States, Germany

Investor stats

  • Total investments: 213
  • Round size: Series A $3.1M–$24M; Series B $3.3M–$65M
  • Lead/follow: 36% lead, 64% follow
  • Last fund: May invest from a new fund soon — last raise in 2019

Portfolio highlights

  • Otoqi — Otoqi is a vehicle delivery platform that develops connected services and logistics solutions for the automotive professionals.
  • Karmen — Karmen offers revenue-based financial solutions such as venture capital and loans to accelerate business growth for SaaS companies.
  • Flexvelop — Flexvelop combines financial technology with circular economy to add innovative values to the core function of equipment funding.Local vendors and online-shops integrate Flexvelop as a seamless embedded payment option. Business customers are now able to #flex new equipment per click right at the point of sale. Insurance is already covered, andour customers have now the weekly option, to buy- or return their equipment, easily. This enables a new world of worry-free and flexible business growth.We #flex business equipment from €300 up to €20.000 per item; e.g. coffee-machines, laptops, gym- or dental-equipment,... anything you need for your business.NEXT GENERATION PAYMENTS + Technological Innovation: fully automatic embedded payment option + Economical Innovation: optionality (rent/buy/return) + insurance included + Ecological Innovation: sustainability (contributing to a circular economy) = Enabling worry-free flexible business developmentForget renting. Forget leasing. Grow smart - flex it!
Show all investments...

Casdin Capital
VC Fund · New York, New York, United States · 10 investments in Life Science startups

Casdin Capital is a fundamental research investment firm focused on the life sciences and healthcare industry. It manages a long-short equity fund and makes investments in early-stage to late-stage private investments. Casdin was launched in 2012 by founder and CIO Eli Casdin and as of October 2020 has approximately $2.2 billion in assets undermanagement.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series B, Series A, Series C
  • Geography: United States, China, France

Investor stats

  • Total investments: 189
  • Round size: Series A $10M–$191M; Series B $32M–$150M; Series C $40M–$200M
  • Lead/follow: 17% lead, 83% follow
  • Last fund: May invest from a new fund soon — raised $30M in 2018

Portfolio highlights

  • Beacon Biosignals — AI + EEG to change the way patients are treated for disorders of the brain.
  • Octave — Octave Bioscience is an early-stage molecular diagnostics company focused on neurodegenerative diseases and conditions. The company was co-founded by Melinda Thomas and William Hagstrom in 2013. Octave Bioscience is headquartered in Menlo Park, California, United States.
  • Parabilis Medicines — Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach.
Show all investments...

Cormorant Asset Management
VC Fund · Boston, Massachusetts, United States · 10 investments in Life Science startups

Cormorant Asset Management is an employee-owned hedge fund sponsor that provides its services to pooled investment vehicles. The firm also focuses on both public and private market innovative companies in the biotechnology and life sciences marketplace.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series B, Series C, Series A
  • Geography: United States, China, Switzerland

Investor stats

  • Total investments: 182
  • Round size: Series A $16M–$93M; Series B $35M–$150M; Series C $33M–$200M
  • Lead/follow: 24% lead, 76% follow
  • Last fund: May invest from a new fund soon — raised $393M in 2019

Portfolio highlights

  • Triveni Bio — Triveni Bio is at the forefront of human genetics, cutting-edge antibody design, and precision medicine, pioneering the identification of new disease targets.
  • Stratus Therapeutics — Garuda Therapeutics is developing off-the-shelf hematopoietic stem cell (HSC) therapies to treat a broad range of severe and life-threatening diseases.
  • Rapport Therapeutics — Precision medicines to match the complexity of the human brain.
Show all investments...

Longwood Fund
VC Fund · Boston, Massachusetts, United States · 10 investments in Life Science startups

Longwood creates and invests in science-based companies that develop novel solutions for important medical problems

Show more...

Investment focus

  • Industry: Biotechnology, Therapeutics, Health Care
  • Stage:Series A, Series B, Series C
  • Geography: United States, United Kingdom, Italy

Investor stats

  • Total investments: 69
  • Round size: Series A $15M–$100M; Series B $25M–$152M; Series C $17M–$100M
  • Lead/follow: 14% lead, 86% follow
  • Last fund: Likely still investing — fund raised in 2023

Portfolio highlights

  • DEM BioPharma — DEM BioPharma is an immuno-oncology company that is working to eradicate cancer by targeting novel innate immune system checkpoints.
  • Newleos Therapeutics — Newleos Therapeutics is a biotech startup dedicated to producing safer and more effective neuroscience medicines.
  • Vertero — Axial Therapeutics is a biotechnology company fundamentally changing the treatment of neurological diseases and disorders by harnessing groundbreaking science in the microbiome-gut-brain axis.
Show all investments...

Development Bank of Wales
VC Fund · Cardiff, Cardiff, United Kingdom · 10 investments in Life Science startups

Development Bank of Wales is an independent company, providing commercial funding to Welsh SMEs. They invests private and public funds, including EU funds.

Show more...

Investment focus

  • Industry: Software, Health Care, Biotechnology
  • Stage:Seed, Debt Financing
  • Geography: United Kingdom, Australia, United States

Investor stats

  • Total investments: 211
  • Round size: Seed $327k–$3.7M; Debt Financing $18k–$2M
  • Lead/follow: 58% lead, 42% follow
  • Last fund: May invest from a new fund soon — raised $25M in 2018

Portfolio highlights

  • Forth — Forth are a group of clinical and digital experts who are passionate about healthcare. They’re part of a new breed of digital healthcare companies who are transforming people’s relationship with their health by using technology to give them more information and help them gain greater control.
  • enModus — Experience the thrill of competing against other players in online casino tournaments! These events offer a unique opportunity to showcase your skills and
  • Antiverse — Designing biologics for 100 challenging targets
Show all investments...

Catalio Capital Management
VC Fund · Baltimore, Maryland, United States · 10 investments in Life Science startups

Catalio Capital Management was created by George Petrocheilos and Dr. Jacob Vogelstein to invest in breakthrough biomedical technology companies created or referred by Catalio Capital Management, an elite group of world-renowned, serial scientist-entrepreneurs.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Life Science
  • Stage:Series A, Series B
  • Geography: United States, Switzerland, Israel

Investor stats

  • Total investments: 114
  • Round size: Series A $18M–$120M; Series B $26M–$150M
  • Lead/follow: 28% lead, 72% follow

Portfolio highlights

  • 9amHealth — 9am.health redesigns all care elements into one digital service individualized around today’s reality of people’s life - always available and convenient, at prices anyone can afford even without insurance. 9am.health focuses on chronic conditions such as diabetes, hypertension, and hyperlipidemia for customers in the United States.
  • Amalgam Rx — The leading digital platform for SaaS-enabled solutions that connect healthcare providers and life sciences companies
  • Parabilis Medicines — Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach.
Show all investments...

Roche Venture Fund
VC Fund · Basel, Basel-Stadt, Switzerland · 10 investments in Life Science startups

We are the corporate venture fund of Roche, a global leader in bringing medicines and in vitro diagnostics to the benefit of patients.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series B, Series A, Series C
  • Geography: United States, United Kingdom, Spain

Investor stats

  • Total investments: 110
  • Round size: Series A $6M–$59M; Series B $10M–$100M; Series C $5M–$105M
  • Lead/follow: 12% lead, 88% follow

Portfolio highlights

  • DiogenX — Welcome to DiogenX. Explore our pioneering research and innovative therapies aimed at transforming diabetes treatment
  • Mironid — Google Analytics is a web analysis service provided by Google. Google utilizes the data collected to track and examine the use of www.mironid.com, to prepare reports on its activities and share them with other Google services. Google may use the data collected to contextualize and personalize the ads of its own advertising network.
  • MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas
Show all investments...

Khosla Ventures
VC Fund · Menlo Park, California, United States · 10 investments in Life Science startups

Khosla Ventures is a venture capital firm that invests in early- to late-stage companies across sectors like AI, healthcare, sustainability, and consumer technology. It manages multiple funds, focusing on startups with innovative technologies or business models. The firm primarily targets sectors like AI, climate tech, digital health, and medtech,offering strategic support to help build long-lasting companies.

Show more...

Investment focus

  • Industry: Software, Artificial Intelligence, Health Care
  • Stage:Series A, Series B, Seed
  • Geography: United States, India, United Kingdom

Investor stats

  • Total investments: 1048
  • Round size: Seed $1.9M–$15M; Series A $5.5M–$40M; Series B $10M–$100M
  • Lead/follow: 40% lead, 60% follow
  • Last fund: Likely still investing — raised $557M in 2022

Portfolio highlights

  • Recraft — The first generative AI design tool that lets users create and edit digital illustrations, vector art, icons, and 3D graphics in a uniform brand style.
  • Loop — Loop Health is bringing ease and choice to patients seeking major medical treatments. We've brought together family physicians, top specialists, and leading hospitals in Pune – to provide options, transparency, and ease to patients and their families. Loop Coordinators help patients match with a doctor, compare treatment costs, get secondopinions, and complete admission formalities – removing the stress and making lives easier for the patient and their families.
  • Big Switch Networks — Arista Registration FormRegister with Arista to access the Customer Portal, Software Downloads and much more! Support PortalOpen a new case, view cases Software DownloadsDownload DMF (BMF) / CCF (BCF) Software Customer SupportSupport Overview, Conta
Show all investments...

Rev1 Ventures
VC Fund · Columbus, Ohio, United States · 9 investments in Life Science startups

Rev1 Ventures provides seed stage venture capital funding in Columbus, Ohio along with startup services, space, mentoring, and connections. Learn more!

Show more...

Investment focus

  • Industry: Software, Health Care, Information Technology
  • Stage:Seed, Series A
  • Geography: United States, Germany

Investor stats

  • Total investments: 191
  • Lead/follow: no public data

Portfolio highlights

  • RedNOx — RedNOx develops breakthrough emissions reduction technology for heavy-duty engines, gensets, and agricultural equipment.
  • InnerActiv — InnerActiv is a cybersecurity software company that protects organizations from insider threats, fraud, and data loss at the endpoint. Built with an AI-driven, behavior-based approach, InnerActiv delivers real-time visibility into how users interact with sensitive data, systems, and devices—detecting risky activity such as data grazing, policytesting, and low-and-slow reconnaissance before it leads to a breach. The platform’s lightweight, encrypted agents and endpoint-first design provide proactive protection, faster response, and seamless integration with existing security stacks.
  • SureImpact — SureImpact is a user-friendly, social services case management software that helps you track and report outcomes, measure participant needs, and demonstrate impact to funders.
Show all investments...

Life Science VC funding at a glance

Stats across 4.7k deals from 4.7k investors.

4.7k
investors
in Life Science startups
4.7k
deals
in Life Science startups
$7.5M
median round
in Life Science startups
41%
lead investors
lead at least one round
22%
Seed
most common funding stage

Access all 4722 VC funds in Life Science startups.

Open List

FAQ

Is Shizune data fresh/accurate?

Shizune has monitored hundreds of funding sources since 2020.

Our investor database is updated every day, so investor data is always fresh.

All metrics are calculated from confirmed public rounds, so the data is accurate.

Can I download investor list?

To download the Life Science VC Funds investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.

You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.

Can I access investor database?

To access all 4722 VC funds investing in Life Science startups and 48,091+ more investors, create a Shizune account.

Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.

The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.

You can enrich with email and download the data.

Does Shizune have investor emails and contacts?

Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.

To guarantee the highest discovery rate, we search across 20+ contact search tools.

To maximize delivery rate and reduce bounce rate, we validate emails.

You can enrich your investor list with Shizune. Download it too.

What is Shizune?

Shizune is a 48,091 investor database updated daily.

With Shizune you can:

  • browse the database
  • use smart matching
  • enrich with emails
  • download

All you need to find investors for your startup.

Who is Shizune for?

Shizune is built for startup founders by startup founders.

If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.

Is Shizune free?

Shizune is free forever. You can search and browse investors for free.

Email search and export are paid features.

For full info, visit our pricing.

Who built Shizune?

Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.

Contact 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!

More investor lists